NC H35

Expands the definition of "opioid antagonist" in G.S. 90-12.7(a) from specifically "naloxone hydrochloride" to include all opioid antagonists approved by the federal Food and Drug Administration for treating drug overdoses.

Modifies G.S. 90-113.27 to allow needle and hypodermic syringe exchange programs to distribute any FDA-approved opioid antagonist kits, rather than being limited to naloxone hydrochloride specifically.

Requires needle and syringe exchange programs to provide personal consultations from staff or volunteers concerning mental health or addiction treatment for each individual requesting services.

Mandates programs report annually to the North Carolina Department of Health and Human Services, Division of Public Health on the number of opioid antagonist kits distributed and referrals provided, using updated terminology reflecting all FDA-approved antagonists.

Takes effect upon becoming law.